Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsKavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola, Gaurang Patel, Ying Hu, Carmelo Romano, Giusy Della Gatta, Trikaldarshi Persaud
Estimating the term…
The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.
A method of treating a patient having glaucoma or increased intraocular pressure (TOP), the method comprising administering an angiopoietin like 7 (ANGPTL7) inhibitor to the patient, wherein the ANGPTL7 inhibitor comprises an antisense molecule that hybridizes to a sequence within an ANGPTL7 mRNA or an ANGPTL7 genomic nucleic acid molecule and decreases expression of the ANGPTL7 polypeptide in a cell in the patient.
Dependencies are inferred from the claim text.